Autonomix Medical, Inc.
No enriched coverage for $AMIX in the last 7 days.
No SEC Form 4 filings for $AMIX in the last 30 days.
See all $AMIX insider activity →Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, August 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedic
Autonomix Medical (NASDAQ: AMIX) received a new U.S. patent (No. 12,714,780) for systems integrating real-time feedback, sensing, and imaging with controlled therapeutic delivery, including neural ablation for cancer pain. The patent covers systems regulating treatment based on physiological feedback and has applications in neuromodulation and targeted ablation. The company believes this strengthens its IP position and supports its technology platform's advancement.
Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
Recent AMIX coverage spans market movers, technology and corporate actions.
The warrant transaction provides immediate cash and dilutes equity, likely pressuring the share price short‑term while funding R&D.
The new patent strengthens Autonomix's IP position but does not immediately affect revenue or cash flow.
Significant pre‑market price jump suggests strong short‑term buying pressure.
The warrant transaction adds cash but increases share count, likely pressuring the stock short‑term.
New patent expands IP portfolio and triggers a sharp price rally.
alphai scores every news story that mentions AMIX with an AI model for sentiment and relevance, and aggregates insider trades from Autonomix Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Autonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules THE WOODLANDS, TX, August 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedic
2 min readAutonomix Medical (NASDAQ: AMIX) received a new U.S. patent (No. 12,714,780) for systems integrating real-time feedback, sensing, and imaging with controlled therapeutic delivery, including neural ablation for cancer pain. The patent covers systems regulating treatment based on physiological feedback and has applications in neuromodulation and targeted ablation. The company believes this strengthens its IP position and supports its technology platform's advancement.
1 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readAutonomix Medical (AMIX) announced a $4.9M warrant inducement agreement with an investor. The deal involves exercising July 2026 warrants for 857,462 shares at $5.75 per share. The company will also issue new warrants for 535,913 shares each, exercisable at $6.25 per share. The transaction is expected to close on August 26, 2026, subject to customary conditions.
2 min readAutonomix Medical (AMIX) received a U.S. patent for its precision nerve sensing and cancer pain therapy technology. The patent covers systems to sense, map, and target nerves associated with tumors and cancer-related pain. The company's shares surged 116.73% to $5.97 in extended trading following the announcement and positive preclinical results for resistant hypertension treatment.
2 min readAutonomix Medical (NASDAQ:AMIX) said it completed a Good Laboratory Practice pre-clinical study for its Autonomix platform, generating safety and performance data in porcine models across multiple anatomical targets, according to the company. The results are expected to support planned FDA submissions as part of its regulatory package.
4 min readAutonomix Medical Inc. (AMIX) shares fell about 33.85% as dilution and warrant-related supply concerns weighed on sentiment. The company filed a prospectus for resale of up to 857,462 shares and previously completed a warrant inducement deal raising about $2.6M. AMIX also reported about $7.0M cash and no long-term debt, but ongoing operating cash outflows.
6 min readAutonomix Medical (AMIX) said the U.S. Patent No. 12,433,670 was issued for systems that sense, map, and selectively target nerves tied to tumors, cancer pain, and autonomic disorders. The patent covers catheter-based tools that record neural signals and deliver energy or agents. AMIX cited IP expansion. AMIX closed at $19.50, up 434.25% Tuesday.
2 min readU.S. indexes rose Tuesday. The article highlights retail-trader attention on several stocks. SpaceX-linked SPCX jumped 9.43% after Starlink subscribers doubled to 12M and cash/backlog were cited. AMD gained 7% on guidance for Q3 revenue around $13B. NVDA was mentioned via Musk comments. ALAB rose after a Q2 EPS and revenue beat. AMIX surged 434% on a new U.S. patent.
7 min readAutonomix Medical (NASDAQ:AMIX) shares rose 386.58% to $17.76 Tuesday after the company obtained a key cancer technology patent, according to Benzinga Pro. The patent covers catheter-based microsurgical tools for recording neural signals and delivering therapy, with claims across multiple cancer types, according to the company.
3 min read
